Jung Ha Kim Selected Research

Coronary Restenosis

1/2021	Effect of Novel Polymer-Free Nitrogen-Doped Titanium Dioxide Film-Coated Coronary Stent Loaded With Mycophenolic Acid.
1/2017	The Control of Drug Release and Vascular Endothelialization after Hyaluronic Acid-Coated Paclitaxel Multi-Layer Coating Stent Implantation in Porcine Coronary Restenosis Model.
1/2017	Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model.
11/2016	A novel polymer-free drug-eluting stent coated with everolimus using nitrogen-doped titanium dioxide film deposition in a porcine coronary restenosis model.
4/2016	Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model.
3/2015	Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model.
11/2014	Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model.
11/2013	Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.
4/2013	Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model.
9/2011	Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jung Ha Kim Research Topics

Disease

12	Coronary Restenosis 01/2021 - 05/2010
10	Inflammation (Inflammations) 08/2017 - 09/2011
8	Hyperplasia 08/2017 - 05/2010
8	Neointima 01/2017 - 05/2011
7	Pathologic Constriction (Stenosis) 01/2021 - 09/2011
3	Neoplasms (Cancer) 07/2018 - 05/2016
3	Bone Resorption 01/2015 - 05/2004
2	MASS syndrome 01/2019 - 02/2016
2	Myocardial Infarction 01/2015 - 02/2011
2	Infarction (Infarctions) 01/2015 - 02/2011
1	Osteoporosis 05/2020
1	Levin type Osteogenesis imperfecta 01/2019
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018
1	Osteoarthritis 01/2018
1	Burns 03/2017
1	Syncope (Fainting) 03/2017
1	COACH syndrome 01/2017
1	Cerebellar Ataxia (Dysmetria) 01/2017
1	Meckel syndrome type 3 01/2017
1	Malaria 01/2017
1	Congenital Hepatic Fibrosis 01/2017
1	Stomach Neoplasms (Stomach Cancer) 05/2016
1	Carcinoma (Carcinomatosis) 05/2016
1	Adenocarcinoma 05/2016
1	Fibrosis (Cirrhosis) 01/2016
1	Ureteral Obstruction 01/2016
1	Necrosis 04/2015
1	Thrombosis (Thrombus) 04/2015
1	Cardiomegaly (Heart Hypertrophy) 05/2014
1	Hypertrophy 05/2014
1	Body Weight (Weight, Body) 05/2014
1	Spasm (Spasms) 06/2012
1	Multiple Myeloma 05/2012
1	Hepatitis C 02/2007
1	Chronic Hepatitis C 02/2007
1	Osteopetrosis 09/2005

Drug/Important Bio-Agent (IBA)

7	FibrinIBA 01/2021 - 04/2013
4	PolymersIBA 01/2021 - 11/2014
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2015
3	Thioctic Acid (Lipoic Acid)IBA 04/2016 - 05/2011
2	Everolimus FDA Link 11/2016 - 11/2013
2	3,3',4,5'-tetrahydroxystilbeneIBA 01/2016 - 05/2014
2	Ezetimibe (Zetia)FDA Link 03/2015 - 05/2010
2	Simvastatin (Zocor)FDA LinkGeneric 03/2015 - 05/2010
2	BESIBA 11/2014 - 11/2013
2	Abciximab (ReoPro)FDA Link 11/2014 - 05/2011
2	MetalsIBA 04/2013 - 05/2011
1	Anabolic AgentsIBA 05/2020
1	Bone Density Conservation AgentsIBA 05/2020
1	Collagen Type I (Type I Collagen)IBA 01/2019
1	AnoctaminsIBA 01/2019
1	methylmethacrylate-methacrylic acid copolymerIBA 07/2018
1	PalmitatesIBA 01/2018
1	Nonesterified Fatty Acids (NEFA)IBA 01/2018
1	Casein Kinase II (Casein Kinase 2)IBA 01/2018
1	Oleic Acid (Oleate)IBA 01/2018
1	Protein Kinases (Protein Kinase)IBA 01/2018
1	NF-kappa B (NF-kB)IBA 09/2017
1	Prasugrel Hydrochloride FDA Link 08/2017
1	Clopidogrel (Plavix)FDA Link 08/2017
1	TicagrelorIBA 08/2017
1	Hyaluronic Acid (Hyaluronan)IBA 01/2017
1	artenimol (dihydroartemisinin)IBA 01/2017
1	Guanosine Triphosphate (GTP)IBA 01/2017
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2017
1	artemisinin (artemisinine)IBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2017
1	titanium dioxide (Titania)FDA Link 11/2016
1	NitrogenIBA 11/2016
1	astaxanthine (astaxanthin)IBA 05/2016
1	Sirolimus (Rapamycin)FDA Link 04/2016
1	Drug CombinationsIBA 04/2016
1	Tartrate-Resistant Acid PhosphataseIBA 02/2016
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2016
1	p38 Mitogen-Activated Protein KinasesIBA 01/2016
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 01/2016
1	Connective Tissue Growth FactorIBA 01/2015
1	fimasartanIBA 01/2015
1	Angiotensin Receptor AntagonistsIBA 01/2015
1	GATA Transcription FactorsIBA 05/2014
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 05/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2013
1	zotarolimusIBA 11/2013
1	Acetylcholine (Acetylcholine Chloride)FDA Link 06/2012
1	Interleukin-3 (Interleukin 3)IBA 05/2012
1	ramiprilatIBA 09/2011
1	Angiotensin IIIBA 09/2011
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 02/2011
1	Sildenafil Citrate (Viagra)FDA Link 02/2011
1	Cathepsin KIBA 07/2009
1	Interferon-alpha (Interferon Alfa)IBA 02/2007
1	Ribavirin (Virazole)FDA LinkGeneric 02/2007
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 09/2005
1	tanshinoneIBA 05/2004

Therapy/Procedure

11	Stents 01/2021 - 05/2011
6	Drug-Eluting Stents 01/2017 - 05/2010
3	Therapeutics 07/2018 - 02/2007
1	First Aid (Aids, First) 03/2017